Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06815497 · ClinicalTrials.gov registry record · Phase 2
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Tyler J Curiel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 2
- Study locations
NCT06815497 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by Tyler J Curiel. The registered enrollment target is 33 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06815497, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by Tyler J Curiel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
Conditions Studied
Interventions
- DRUG Telmisartan
Study Locations (2)
New Hampshire
- Dartmouth Hitchcock - Lebanon
- Dartmouth-Hitchcock Manchester - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-01-21 |
| Est. Completion | 2029-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06815497
The ClinicalTrials.gov registry entry for NCT06815497 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Tyler J Curiel, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Telmisartan is the first listed.
NCT06815497 reports 2 study locations spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT06815497 about?
NCT06815497 is a clinical study titled "Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer". The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
What is the current status of trial NCT06815497?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2026-01-21. Estimated completion is 2029-05-14.
What conditions does trial NCT06815497 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06815497?
The interventions under investigation include: Telmisartan (DRUG).
Who is sponsoring clinical trial NCT06815497?
This trial is sponsored by Tyler J Curiel, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06815497 being conducted?
This trial has 2 study locations across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.